Assignee
FIVE PRIME THERAPEUTICS INC
US·53 granted patents·51 pending applications·208 citations·filing 2005–2025
Top patents by PatentIndex Score
104 records- 0197US7678890B2Compositions and methods of treating disease with FGFR fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2006·Granted Mar 16, 2010·67 cites·3 claims
- 0295US11155615B2Anti-ROR1 antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Oct 26, 2021·13 cites·13 claims
- 0395US9765147B2Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Sep 19, 2017·25 cites·31 claims
- 0495US7982014B2FGFR3-IIIc fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2010·Granted Jul 19, 2011·24 cites·12 claims
- 0592US10221244B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2017·Granted Mar 5, 2019·10 cites·31 claims
- 0691US11306144B2B7-H4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Apr 19, 2022·6 cites·45 claims
- 0790US11814431B2B7-H4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Nov 14, 2023·3 cites·48 claims
- 0889US9957327B2Antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2016·Granted May 1, 2018·5 cites·24 claims
- 0989US7776564B2Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of useFIVE PRIME THERAPEUTICS INC·Filed 2005·Granted Aug 17, 2010·15 cites·13 claims
- 1088US10618967B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Apr 14, 2020·5 cites·31 claims
- 1186US10273281B2CD80 extracellular domain polypeptides and their use in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Apr 30, 2019·7 cites·40 claims
- 1284US10172937B2Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Jan 8, 2019·5 cites·32 claims
- 1383US11091555B2Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapyFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Aug 17, 2021·3 cites·20 claims
- 1482US7795404B1Human soluble notch receptor ligandsFIVE PRIME THERAPEUTICS INC·Filed 2007·Granted Sep 14, 2010·8 cites·14 claims
- 1581US10221243B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Mar 5, 2019·4 cites·23 claims
- 1681US2024043542A1B7-h4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1781US2025206822A1Antibodies Binding to Vista at Acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1881US2023212299A1Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for CancerFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1980US2022153851A1Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2079US12195535B2Antibodies binding to VISTA at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2023·Granted Jan 14, 2025·0 cites·37 claims
- 2178US12365719B2CD80 extracellular domain polypeptides and their use in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2022·Granted Jul 22, 2025·0 cites·18 claims
- 2277US12173069B2Antibodies binding to vista at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Dec 24, 2024·1 cites·28 claims
- 2376US12435136B2Antibodies binding to ILT4FIVE PRIME THERAPEUTICS INC·Filed 2022·Granted Oct 7, 2025·0 cites·42 claims
- 2476US10730949B2Method of treating PVNS with anti-CSF1R antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Aug 4, 2020·1 cites·35 claims
- 2575US12465636B2Method of making afucosylated anti-FGFR2IIIB antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2021·Granted Nov 11, 2025·0 cites·13 claims
- 2675US10040858B2Anti-CSF1R antibodies for treating PVNSFIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Aug 7, 2018·2 cites·56 claims
- 2775US9200075B2Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2014·Granted Dec 1, 2015·1 cites·23 claims
- 2875US2024317864A1B7-h4 antibody dosing regimensFIVE PRIME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2975US2025129166A1Antibodies Binding to Vista at Acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3074US11186646B2Antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Nov 30, 2021·0 cites·19 claims
- 3174US10982001B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Apr 20, 2021·1 cites·17 claims
- 3273US2009286954A1Human cDNA Clones Comprising Polynucleotides Encoding Polypeptides and Methods of Their UseFIVE PRIME THERAPEUTICS INC·Filed 2009·Application pending·0 cites
- 3372US2023013293A1B7-h4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3471US11566076B2Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancersFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Jan 31, 2023·0 cites·25 claims
- 3571US11098103B2CD80 extracellular domain polypeptides and their use in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Aug 24, 2021·0 cites·8 claims
- 3670US2008182974A1Human cDNA clones comprising polynucleotides encoding polypeptides and methods of their useFIVE PRIME THERAPEUTICS INC·Filed 2007·Application pending·0 cites
- 3769US10562970B2Antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Feb 18, 2020·0 cites·28 claims
- 3869US9775881B2Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECDFIVE PRIME THERAPEUTICS INC·Filed 2014·Granted Oct 3, 2017·1 cites·19 claims
- 3969US2023287123A1B7-h4 antibody dosing regimensFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4069US2026085123A1Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4169US2023052212A1Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4269US2025269016A1Afucosylated Anti-FGFR2IIIB AntibodiesFIVE PRIME THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4368US10822421B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Nov 3, 2020·0 cites·37 claims
- 4468US2015203566A1Fgfr1 extracellular domain combination therapiesFIVE PRIME THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4567US12319738B2Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancerFIVE PRIME THERAPEUTICS INC·Filed 2021·Granted Jun 3, 2025·0 cites·12 claims
- 4667US9475871B2Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2014·Granted Oct 25, 2016·0 cites·22 claims
- 4766US11235059B2Afucosylated anti-FGFR2IIIB antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Feb 1, 2022·0 cites·59 claims
- 4866US10975153B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Apr 13, 2021·1 cites·29 claims
- 4966US9192683B2Methods of treating disease with FGFR1 fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2013·Granted Nov 24, 2015·0 cites·21 claims
- 5066US2021277130A1Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 104 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →